Benzinga - Dec 18th, 2024
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profileData includes complete results from cohort 1 and initial results from cohort 2Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 millionCompany to host conference call and webcast today at 8:00 a.m. ET / 5:00 a.m. PTBURLINGAME, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The data demonstrated a favorable safety profile and efficacy profile, supporting the ongoing development of soquelitinib for atopic dermatitis and the potential of ITK inhibition as a novel mechanism of action for other immune diseases."We are pleased with the early results of our soquelitinib Phase 1 atopic dermatitis clinical trial, which show an attractive potential product profile at the lowest dose we are studying," said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. "The data show consistent signs of efficacy, combined with a novel mechanism of action, a convenient oral route of administration and a favorable safety profile. This is also supported by an analysis of serum cytokine levels, which show a possible relationship between clinical response and reductions in IL-5, IL-17, IL-31, IL-33 and TSLP, along with a trend for TARC. We believe the data highlights soquelitinib's potential as a new treatment option for atopic dermatitis and the broader opportunity for ITK inhibition for other immune related diseases. In addition to blocking the production of multiple inflammatory cytokines, soquelitinib may have persistent direct effects on immune cell function that act to regulate aberrant immune responses. We look forward to completing the Phase 1 trial and initiating other trials with soquelitinib for immune diseases."Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial DesignThe randomized, double-blind, placebo-controlled Phase 1 clinical trial is planned to enroll 64 patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic therapy. Patients are enrolled into one of four dosing cohorts in a 3:1 ratio (12 active and 4 placebo) to receive either soquelitinib or placebo. The cohorts are sequentially enrolled and will examine 100 mg oral twice per day, 200 mg oral once per day, 200 mg oral twice per day and 400 mg oral once per day. Patients are treated for 28 days and are then followed for an additional 30 days with no therapy.These doses were selected based on the Company's prior experience evaluating soquelitinib in T cell lymphoma patients. The doses in the atopic dermatitis trial bracket the 200 mg oral twice a day dosing regimen, which is the level that has been shown to provide complete ITK occupancy and that is being evaluated in the Company's ongoing registrational Phase 3 clinical trial of soquelitinib in peripheral T cell lymphoma.The primary endpoints include safety and tolerability, and efficacy, measured by improvement in Eczema Area and Severity Index (EASI) score, Investigator Global Assessment (IGA), reduction in itch and various cytokine biomarkers. EASI scores are also evaluated by the percent of patients that achieve a specified percent reduction in EASI score – EASI 50 for patients that achieved a 50% reduction; EASI 75 for a 75% reduction; and EASI 90 for a 90% reduction. Corvus and a data monitoring committee will be able to monitor the data from the trial as the trial progresses.Soquelitinib Interim Data from the Atopic Dermatitis Phase 1 Clinical TrialThe Company is reporting complete results from Cohort 1 of the trial, which includes 16 patients (12 that received soquelitinib 100 mg oral twice per day and four that received placebo) with follow up at 28 days and at 58 days. At 58 days, two patients in the soquelitinib group were not available for follow up. The soquelitinib and placebo patients were well matched; see Table 1 below for patient characteristics. Table 1: Cohort 1 Patient Characteristics SoquelitinibPlacebo (N=12)(N=4)Age, mean (range), yrs46.3 (30–66)50.5 (32–62)Gender, male n (%)7 (58.3)4 (100)Race/ethnicity, n (%) Asian2 (16.7)0 (0) Black or African American6 (50)4 (100) White3 (25)0 (0) Hispanic or Latino1 (8.3)0 (0)Baseline EASI, mean (range)20.4 (15.0–46.6)18.5 (14.9–24.8)Baseline IGA, mean (range)3.0 (2–4)3.3 (3–4)Prior AD therapies, n (%) Topical Corticosteroids11 (91.7)4 (100) Systemic therapies3 (25)Full story available on Benzinga.com
Benzinga - Dec 18th, 2024
Perma-Fix Announces Pricing of $22 Million Public Offering of Common Stock
ATLANTA, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) ("Perma-Fix" or the "Company"), today announced the pricing of its previously announced underwritten public offering of 2,200,000 shares of its common stock at a price to the public of $10.00 per share. Perma-Fix expects the gross proceeds from the offering to be approximately $22 million before deducting the underwriting discount and other estimated offering expenses. In connection with the offering, Perma-Fix has granted the underwriter a 30-day option to purchase up to 330,000 additional shares of its common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about December 19, 2024, subject to the satisfaction of customary closing conditions.Perma-Fix intends to use the net proceeds from the offering to fund (i) continued R&D and business development relating to the Company's patent-pending Perma-FAS process for the destruction of PFAS, as well as the cost of installing at least one second-generation Perma-FAS commercial treatment unit; (ii) ongoing facility cap-ex and maintenance costs; as well as (iii) general corporate and working capital purposes.Craig-Hallum is acting as sole managing underwriter for the offering. Wellington Shields is acting as financial advisor to the Company for the offering.The shares described above are being offered by Perma-Fix pursuant to a shelf registration statement on Form S-3 (File No. 333-283555), including a base prospectus, that was filed with the Securities and Exchange Commission (SEC) and declared effective on December 12, 2024. The offering is being made only by means of a prospectus supplement, ...Full story available on Benzinga.com
Globe Newswire - Dec 18th, 2024
Amesite Announces NurseMagicTM Enterprise Contract Wins in High Growth Companies with Hundreds of Franchise Owners
Company Generating Recurring Revenue in $330 Billion Revenue Home Health and Home Care Industries Company Generating Recurring Revenue in $330 Billion Revenue Home Health and Home Care Industries
Globe Newswire - Dec 18th, 2024
Mesoblast to be Added to Nasdaq Biotechnology Index
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to the Nasdaq Biotechnology Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq index. Mesoblast’s inclusion in the NBI will be effective after the U.S. market opens on Monday, December 23, 2024.
Globe Newswire - Dec 18th, 2024
Bioprocess Validation Market to hit USD 1.03 billion by 2032, says Global Market Insights Inc.
Bioprocess validation industry is projected to witness a CAGR of 10.7% during the period 2024-2032. This growth can be attributed to stringent regulations regarding safety and quality. Bioprocess validation industry is projected to witness a CAGR of 10.7% during the period 2024-2032. This growth can be attributed to stringent regulations regarding safety and quality.
Pr Newswire - Dec 18th, 2024
LION ELECTRIC FILES APPLICATION FOR CREDITOR PROTECTION UNDER THE CCAA
MONTREAL, Dec. 18, 2024 /PRNewswire/ - The Lion Electric Company (NYSE: LEV) (TSX: LEV) ("Lion" or the "Company"), a leading manufacturer of all-electric medium and heavy-duty urban vehicles, announced today that the Company and its subsidiaries have applied to the Superior Court of...
Pr Newswire - Dec 18th, 2024
Valour Digital Securities Limited and The Hashgraph Group (THG) Expand Access to Hedera HBAR ETP with Euronext Listing
New Hedera HBAR ETP Launched on Euronext: Valour Digital Securities Limited has introduced a new Hedera HBAR ETP (ISIN: GB00BRC6JM96) on Euronext Amsterdam, expanding access to Hedera's native token, HBAR, for European investors. Distinct Offering: This new listing represents the first...
Forbes - Dec 18th, 2024
Here’s How Much Being Ticketed Will Hike Car Insurance Rates, Study Shows
The worst offenses can boost one's rates by 70-80% or more.
Benzinga - Dec 18th, 2024
Oleate Esters Market is Set to Reach US$ 3,612.3 Million with Growing at a 5.6% CAGR by 2034 | Fact.MR Report
Rockville, MD, Dec. 18, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global oleate ester market is estimated to reach a valuation of US$ 2,094.8 Million in 2024 and is expected to grow at a CAGR of 5.6% during the forecast period of (2024 to 2034).Rising environmental awareness and growing regulations on the use of chemicals, oleate esters are being produced from renewable and non-polluting resources by manufacturers to keep up to the needs. The recent changes by producers can be noted with an emphasis on the procurements of palm, soy and sunflower oleo-chemicals that fully replace their petroleum-based counterparts which is more environmentally friendly. This is because customers have become more health-conscious over the years and prefer safe oleate which meet their quality standards.In order to enhance the performance and adaptability of oleate esters to changing needs, manufacturers allocate some of their resources to research and development. For example, advances in technology enabled the development of oleate esters with enhanced stability, solubility and emulsification properties which has further expanded their use in various products including cosmetic agents and industrial lubricants.For More Insights into the Market, Request a Sample of this Report:https://www.factmr.com/connectus/sample?flag=S&rep_id=7433Key Takeaways from the Market Study:The global oleate ester market is projected to grow at 5.9% CAGR and reach US$ 3,612.3 Million by 2034The East Asia is a prominent region that is estimated to hold a market share of 33.1% in 2034Predominating market players include Wilmar International Ltd., Kao Corporation, Emery Oleochemicals, Victorian Chemical Company, Italmatch Chemical S.p.A., Croda International Plc., and INEOS Group.Ethyl oleate under oleate type is estimated to grow at a CAGR of 5.8% reaching a valuation of US$ 942.8 Million by 2034"Oleate ...Full story available on Benzinga.com
Lehighvalleylive - Dec 18th, 2024
Wrestling team rankings for Dec. 18, 2024: Familiar face starts on top
The rankings expand to 12 teams this winter.
Globe Newswire - Dec 18th, 2024
Les Batteries à Base de Silicium de Novacium Offrent un Retour d’Énergie Cumulé Supérieur sur 650 Cycles, comparativement aux Batteries à base de Graphite Artificiel de Haute Qualité
MONTRÉAL, 18 déc. 2024 (GLOBE NEWSWIRE) -- HPQ Silicium inc. (« HPQ » ou « la Société ») (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), une entreprise technologique spécialisée dans l'ingénierie verte des matériaux à base de silice et de silicium a le plaisir d’informer les actionnaires sur les plus récentes avancées significatives réalisées par sa société affiliée française, NOVACIUM SAS (« Novacium »), dans le domaine des batteries.
The Advocate - Dec 18th, 2024
What's behind a 're-energized' Cam Jordan? Look at the Saints' coaching changes.
Cam Jordan is not faster than Jayden Daniels. And realistically, at age 35, the New Orleans Saints defensive end shouldn’t have much of a chance against Jayden Daniels.
ABC News - Dec 18th, 2024
How to avoid financial stress during the holiday season
The holidays are meant to be a time of celebration with family and friends
ABC News - Dec 18th, 2024
Owner of Britain's Guardian newspaper confirms sale of Sunday sister paper The Observer to Tortoise Media
Owner of Britain's Guardian newspaper confirms sale of Sunday sister paper The Observer to Tortoise Media
So long TGI Fridays, hello Dunkin: NYC lost a lot of chain stores this year
Duane Reade is among the chain retailers that lost locations in New York City over the past year. More than 100 chain store locations shuttered across the five boroughs, though some popular brands expanded. [ more › ]
The Denver Post - Dec 18th, 2024
Asking Eric: Husband’s connection with “professional tease” tests marriage
He told me I'm overreacting even though the language, even the emojis used, are his usual tone.
Baltimore Sun - Dec 18th, 2024
Ravens WR Zay Flowers says Steelers’ defense doesn’t do anything to stress him
Ravens WR Zay Flowers says the Steelers' defense doesn't stress him, but Baltimore's offense struggled with Pittsburgh in Week 11.
Whyy - Dec 18th, 2024
Georgetown’s Pallet Village breaks ground on community center, expanding support for residents getting back on their feet
A 2,000-square-foot community center is under construction with a kitchen, meeting rooms and office spaces to support residents in transition.
Lit Hub Daily: December 18, 2024
A Christmas Carol might be Charles Dickens’s best known Christmas ghost story, but it definitely isn’t his only one. Olivia Rutigliano recommends more of Dickens’s spooky Yuletide reads. | Lit Hub Reading Lists Who should you ask about the best poems of 2024? Poets, of course. And their picks are all available to read online [...]
Raw Story - Dec 18th, 2024
'Tired of Amazon's lies,' California Teamsters join strike threat
Amazon faces a growing threat of a major walkout in the United States, with the International Brotherhood of Teamsters announcing Tuesday that workers at four of the online retail giant's Southern California facilities have "overwhelmingly" voted to authorize strikes, joining employees at sites in Illinois and New York City.The announcement for DFX4, DAX5, KSBD, and DAX8 in California came after authorizations at the Amazon delivery station DIL7 in Skokie, Illinois on Monday as well as the Staten Island warehouse JFK8 and the DBK4 delivery station in Queens on Friday. Workers at all seven sites want Amazon to recognize their union and negotiate wages, benefits, and working conditions."It's past time that we fight for the pay and benefits we deserve," Raymond Scarborough, a driver at DFX4 in Victorville, said in a Tuesday statement. "Amazon isn't going to bully us out of demanding our rights."Fellow driver Alexis Ayala, who is based at DAX5 in the City of Industry, declared that "we're tired of Amazon's lies.""Amazon is responsible for our low pay and unsafe working conditions," Ayala continued. "My co-workers and I are ready to stand with our brothers and sisters around the country and fight back against this abusive company."Following the NYC votes, the Teamsters gave Amazon until Sunday to start talks. The union said Tuesday that "after ignoring a December 15 deadline from the Teamsters to come to the bargaining table, Amazon now faces potential large-scale labor actions at a critical time of year when the company should be putting workers and customers ahead of corporate profits."Tobias Cheng, a worker at the KSBD air hub in San Bernardino, also highlighted the anticipated impact of a holiday season strike."We know how important our air hub is to Amazon's operations," Cheng said. "If Amazon forces a strike, it might have a serious impact on customers throughout the region and beyond."Increasing pressure on Amazon to improve conditions, U.S. Senate Committee on Health, Education, Labor, and Pensions Chair Bernie Sanders (I-Vt.) on Monday published a report detailing how, as he put it, "executives repeatedly chose to put profits ahead of the health and safety of its workers by ignoring recommendations that would substantially reduce injuries at its warehouses."While Amazon—which was founded by Jeff Bezos, the second-richest man on Earth—released a lengthy statement decrying the report as "misleading," Teamsters leaders and unionized workers have echoed its conclusions in recent days."The corporate elitists who run Amazon are leaving workers with no choice," Teamsters general president Sean O'Brien said of the looming strikes on Tuesday. "Greedy executives are pushing thousands of hardworking Americans to the brink.""Amazon rakes in more money than anybody, they subject workers to injury and abuse at every turn, and they illegally claim not to be the rightful employer of nearly half their workforce," he asserted. "This rigged system cannot continue. Amazon must be held accountable to workers and consumers alike. If workers are forced onto the picket line, Amazon will be striking itself."Riley Holzworth, a worker at DIL7, similarly noted Monday that "Amazon is one of the biggest companies on Earth, but we are struggling to pay our bills.""Other workers are seeing our example and joining our movement," Holzworth added, "because we are only going to get the treatment we deserve if we fight for it."
